Neogene Therapeutics Announces Exclusive License with the National Cancer Institute for a Portfolio of T Cell Receptors (TCR) Targeting KRAS and TP53 Mutations for the Treatment of Cancer

Portfolio of TCRs developed in the laboratory of immunotherapy pioneer Steven Rosenberg, M.D., Ph.D. at the National Cancer Institute, combined with Neogene’s proprietary TCR isolation platform, provides expanded opportunities to target multiple neoantigens in individual patients Neogene plans to evaluate both autologous and allogeneic T cell therapies targeting neoantigens in a broad spectrum of solid […]

Neogene Therapeutics Appoints Raphaël Rousseau, M.D., Ph.D., as Chief Medical Officer

Dr. Rousseau brings extensive scientific expertise and industry experience in the development of T cell therapies and will lead Neogene’s efforts to advance next-generation, fully individualized T cell therapies into the clinic SANTA MONICA, Calif., and AMSTERDAM, December 16, 2021 – Neogene Therapeutics, Inc., a preclinical stage biotechnology company pioneering a new class of fully […]